Jason Butler
Stock Analyst at JMP Securities
(4.60)
# 239
Out of 5,008 analysts
141
Total ratings
52.08%
Success rate
34.85%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $29 → $11 | $10.17 | +8.16% | 11 | Sep 2, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $87.01 | +9.18% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $26.44 | +5.90% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $21.54 | +71.77% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $13.09 | +197.94% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $3.31 | +81.27% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $53.49 | +86.95% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $21.00 | +80.95% | 8 | May 7, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $60.17 | +29.63% | 16 | Apr 10, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $10.19 | +76.64% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.09 | +29.45% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $797.35 | -12.08% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.14 | +225.44% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $8.76 | +2.74% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $66.02 | +10.57% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $5.97 | +50.75% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.86 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.09 | +71.33% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.52 | +1,347.37% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.18 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $7.55 | +556,191.39% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $11.08 | +946.93% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.29 | +109.79% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.67 | - | 1 | Dec 2, 2020 |
Prothena Corporation
Sep 2, 2025
Maintains: Market Outperform
Price Target: $29 → $11
Current: $10.17
Upside: +8.16%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $87.01
Upside: +9.18%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $26.44
Upside: +5.90%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $21.54
Upside: +71.77%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $13.09
Upside: +197.94%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.31
Upside: +81.27%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $53.49
Upside: +86.95%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $21.00
Upside: +80.95%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $60.17
Upside: +29.63%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $10.19
Upside: +76.64%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.09
Upside: +29.45%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $797.35
Upside: -12.08%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.14
Upside: +225.44%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $8.76
Upside: +2.74%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $66.02
Upside: +10.57%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $5.97
Upside: +50.75%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.86
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.09
Upside: +71.33%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.52
Upside: +1,347.37%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.18
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $7.55
Upside: +556,191.39%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $11.08
Upside: +946.93%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.29
Upside: +109.79%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.67
Upside: -